The finding that reducing normal huntingtin alongside mutant protein yields the same benefit contradicts the assumption that selective mutant targeting is necessary. This challenges current therapeutic strategies and suggests unknown roles of wild-type huntingtin in disease pathology. Gap type: contradiction Source paper: Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. (None, None, PMID:22726834)
Landscape Summary: Why does wild-type huntingtin reduction produce equivalent therapeutic benefit as mutant-specific targeting? is a 0.83 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Why does wild-type huntingtin reduction produce equivalent therapeutic benefit as mutant-specific targeting? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: